Hairy-cell leukemia: 30 Cases and a review of the literature;La leucémie à tricholeucocytes: Mise au point à partir de l'étude de 30 observations

Annales de Medecine Interne

Volumn 154, Issue 7, 2003, Pages 435-440

  Malfuson, Jean Valère ^a   Gisserot, Olivier ^b   Cremades, Serge ^b   Doghmi, Kamal ^a   Fagot, Thierry ^a   Souleau, Bertrand ^a,c   De Revel, Thierry ^a,c   De Jaureguiberry, Jean Pierre ^b   Nedellec, Gérard ^a,c  

^a PERCY MILITARY HOSPITAL   (France)

^b Military Teaching Hospital Sainte Anne   (France)

^c University of Paris Descartes   (France)

Author keywords

Hairy cell leukemia; Survey; Treatment

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; PURINE ANTAGONIST;

ADULT; ANEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; MALE; PROGNOSIS; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 1642430575     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. TROUSSARD X, MALOISEL F, FLANDRIN G: Hairy cell leukemia. What is new forty years after the first description? Hematol Cell Ther, 1998; 40: 139-48.
2. SAMSON T, GEROME P, SOLER C, SOULEAU B, DE REVEL T, NEDELLEC G, LE VAGUERESSE R: Immunophénotypage et hémopathies lymphoïdes chroniques. Med Armees, 2000; 28: 13-18.
3. HARVEY M, GOLOMB MD, CATOVSKY D, GOLDE D: Hairy cell leukemia, a clinical review based on 71 cases. Ann Intern Med, 1978; 89 (part 1): 677-783.
4. CLAVEL J, MANDEREAU L, CORDIER S, LE GOASTER C, HEMON D, CONSO F, FLANDRIN G: Hairy cell leukemia, occupation, and smoking. Br J Haematol, 1995; 91: 154-61.
5. TROUSSARD X: Leucémie à tricholeucocytes. Encycl Med Chir - Hématologie, 13-014-H-10, 2000, 8p.
6. MERCIECA J, PUGA M, MATUTES E, MOSKOVIC E, SALIM S, CATOVSKY D: Incidence and significance of abdominal lymphadenopathy in hairy cell leukemia. Leuk Lymph, 1994; 14 (suppl 1): 79-83.
7. MERCIECA J, MATUTES E, EMMETT E, COLES H, CATOVSKY D: 2-chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol, 1996; 93: 409-11.
8. SAINATI L, MATUTES E, DE OLIVEIRA MP, RANI S, LAMPERT IA, CATOVSKY D: A variant form of hairy cell leukemia resistant to interferon: clinical and phenotypic characteristics of 17 patients. Blood, 1990; 76: 157-62.
9. MALOISEL F, ANDRES E, TROUSSARD X, HERBRECHT R, DUFOUR P: Aspects thérapeutiques de la leucémie à tricholeucocytes. Presse Med, 1999; 28: 1887-94.
10. TROUSSARD X, FLANDRIN G: An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leuk Lymph, 1994; 14 (suppl 1): 99-105.
11. CAPNIST G, FEDERICO M, CHISESI T, et al.: Long-term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of HCL. Leuk Lymph, 1994; 14 (suppl 1): 457-64.
12. RIBEIRO P, BOUAFIA F, PEAUD PY, BLANC M, SALLES B, SALLES G, et al.: Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer, 1999; 85: 65-71.
13. DEARDEN CE, MATUTES E, HILDITCH BL, SWANSBURY GJ, CATOVSKY D: Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatine or cladribine. Br J Haematol, 1999; 106: 515-9.
14. FLINN IW, KOPECKY KJ, FOUCAR MK, HEAD D, BENNETT JM, HUTCHINSON R, et al: Long-term follow-up of remission duration, mortality, and second malignacies in hairy cell leukemia patients treated with pentostatin. Blood, 2000; 96: 2881-6.
15. CHACKO J, MURPHY C, DUGGAN C, O'BRIAIN DS, BROWNE PV, MCCANN SR: Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukemia. Br J Haematol, 1999; 105: 1145-50.
16. CHESON BD, VENA DA, BARETT J, FREIDLIN B: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol, 1999; 17: 2454-60.
17. SAVEN A, BURIAN C, KOZIOL J, PIRO L: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood, 1998; 92: 1918-26.
18. SAVEN A, BURIAN C, ADUSUMALLI J, KOZIOL J. Filgrastrim for cladribine-inducted neutropenic fever in patients with hairy cell leukemia: Blood, 1999; 93: 2471-7.
19. JACOBS RH, VOKES EE, GOLOMB HM: Second malignancies in hairy cell leukemia. Cancer, 1985; 56: 1462-7.
20. KAMPMEIER P, SPIELBERGER R, DICKSTEIN J, MICK R, GOLOMB H, VARDIMAN JW: Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assesment. Blood, 1994; 83: 2931-8.
21. HOFFMAN MA, JANSON D, ROSE E, KAI KR: Treatment of hairy cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol, 1997; 15: 1138-42.
22. FEDERICO M, ZINZANI PL, FRASSOLDATI A, VINCETI M, MODE A, ANNINO L, et al.: Risk of second cancer in patients with hairy cell leukemia. Long-term follow-up. J Clin Oncol, 2002; 20: 638-46.
23. ROSE C, AUXENFANTS E, NOEL MP, MAHIEU M, DEMORY JL, CROXO C, et al.: Tuberculosis, Mycobacterium infection and hairy cell leukemia. Presse Med, 1997; 26: 110-4.
24. HASLER P, KISTLER H, GERBER H: Vasculitides in hairy cell leukemia. Semin Arthritis Rheum, 1995; 25: 134-42.
25. QUESADA JR, KEATING MJ, LIBSHITZ HI, LIAMAS L: Bone involvement in hairy cell leukemia. Am J Med, 1983; 74: 228-31.
26. FILLEUIL B, DELANNOY A, FERRANT A, ZENEBERGH A, VAN DAELE S, BOSLY A, et al.: A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia, 1994; 8: 1153-6.
27. THALER J, GRUNEWALD K, GATTRINGER C, HO A, WEYRER K, DIETZE O, et al.: Long-term follow-up of patients with hairy cell leukemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol, 1993; 84: 75-82.
28. HOFFMAN M, AUERBACH L: Bone marrow remission of hairy cell leukemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol, 2000; 109: 900-1.
29. HAGBERG H, LUNDHOLM L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Br J Haematol, 2001; 115: 609-11.
30. KREITMAN RJ, WILSON WH, BERGERON K, RAGGIO M, STELTLER-STEVENSON M, FITZGERALD DJ, et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia. N Engl J Med, 2001; 345: 241-5.